Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season

Journal of Infection and Chemotherapy

Volumn 21, Issue 11, 2015, Pages 802-807

  Ikematsu, Hideyuki ^a   Kawai, Naoki ^a   Iwaki, Norio ^a   Kashiwagi, Seizaburo ^a  

^a Japan Physician's Association   (Japan)

Author keywords

Effectiveness; IC50; Laninamivir; Long acting neuraminidase inhibitor

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; INFLUENZA VACCINE; LANINAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; IC50; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; JAPAN; MAJOR CLINICAL STUDY; MALE; RECOMMENDED DRUG DOSE; SEASONAL INFLUENZA; SINGLE DRUG DOSE; STRAIN DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTIVITY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; PATHOPHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; CHILD; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MALE; ZANAMIVIR;

EID: 84946493168     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.08.013     Document Type: Article

References (19)

1. Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 2009, 46:481-484.
2. Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the advisory committee on immunization practices (ACIP) MMWR 2011, 60:1-24.
3. Kawai N., Ikematsu H., Hirotsu N., Maeda T., Kawashima T., Tanaka O., et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009, 49:1828-1835.
4. Kawai N., Ikematsu H., Iwaki N., Kondou K., Hirotsu N., Kawashima T., et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009, 59:207-212.
5. Sugaya N., Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010, 54:2575-2582.
6. Watanabe A., Chang S.-C., Kim M.J., Chu D.W., Ohashi Y. Longacting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010, 51:1167-1175.
7. Ikematsu H., Kawai N., Iwaki N., Kashiwagi S. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season. J Infect Chemother 2014, 20:81-85.
8. Ikematsu H., Kawai N., Iwaki N., Kashiwagi S. Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons. J Infect Chemother 2014, 20:799-803.
9. Ikematsu H., Kawai N., Kashiwagi S. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. J Infect Chemother 2012, 18:529-533.
10. Nakauchi M., Yasui Y., Miyoshi T., Minagawa H., Tanaka T., Tashiro M., et al. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods 2011, 171:156-162.
11. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009, 53:186-192.
12. IASR 2014; 35: 258-261 [in Japanese].
13. SENTINEL-REPORTING DISEASES (WEEKLY & MONTHLY) Number of cases and cases per sentinel by age group, sex, and prefecture-2009, Grp_07_1. http://idsc.nih.go.jp/idwr/CDROM/Kako/H21/GrpList.html.
14. Kawai N., Ikematsu H., Iwaki N., Maeda T., Satoh I., Hirotsu N., et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006, 43:439-444.
15. Kawai N., Ikematsu H., Iwaki N., Kawashima T., Maeda T., Mitsuoka S., et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect 2007, 55:267-272.
16. Ikematsu H., Kawai N., Iwaki N., Kashiwagi S. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2011-2012 season in Japan. J Infect Chemother 2014, 20:77-80.
17. Ikematsu H., Kawai N., Iwaki N., Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. J Infect Chemother 2015, 21:39-42.
18. http://www.nih.go.jp/niid/ja/influ-resist.html.
19. Kashiwagi S., Yoshida S., Yamaguchi H., Niwa S., Mitsui N., Tanigawa M. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents 2012, 40:381-388.